The SACT time to first treatment (TTFT) dashboard reports the time taken for patients to be treated with SACT drugs once they have been approved by the National Institute of Health and Care Excellence (NICE) for routine commissioning in the NHS. The dashboard includes SACT drugs in Section B of the NICE CDF list (NICE & NHS England approved cancer drugs/indications routinely funded by NHS England from 1 April 2016, including CDF and non-CDF approved drugs). All treatments with a publication date prior to 1 January 2019 have been excluded from analysis. The dashboard uses systemic anti-cancer therapy (SACT) data submitted by NHS trusts and provides a summary measure for England displaying the interquartile range (including mean and median averages). Available filter selections include drug and/or cancer type; alongside filtering for drugs previously available through the Cancer Drugs Fund (CDF) or the early access to medicines scheme (EAMS).
The analysis presented in this report uses routine data reported by NHS Trusts in England through their monthly routine SACT data uploads.
The SACT data has been provided by patients and collected by the NHS as part of their care and support. The data is collated, maintained and quality assured by the National Disease Registration Service, which is part of NHS England.
Providing routine information on the equity of access of new SACT drugs is imperative to gain a greater understanding of the care delivered throughout the NHS. This dashboard aims to improve cancer outcomes for patients - through identifying variation in uptake to support the understanding, and then improvement, in equitable access of new SACT drugs across the country.
Systemic Anti-Cancer Therapy (SACT) data set
The SACT dataset is a population-based resource of SACT activity reported routinely by NHS Trusts in England. Data are collected on the SACT treatments of adult and paediatric patients, delivered in secondary and tertiary settings with the intention of improving survival, delaying further cancer progression or development, and improving disease-free or progression-free survival.
The CancerStats2 reporting portal (opens in a new window) gives registered users access to interactive SACT data reports. The portal does not provide identifiable data but it does have detailed local data. To ensure this data is secure it is only available through the NHS N3 network. Users must register on the homepage.
The CancerStats2 TTFT dashboard (opens in a new window) contains results at trust and cancer alliance level, alongside a summary measure for England.
Please note that the CancerStats2 platform requires an N3/HSCN secure network connection. To ensure the best user experience, we encourage the use of modern web browsers such as Google Chrome, Mozilla Firefox or Microsoft Edge to access the platform. A small number of platform users have reported issues when opening reports using Internet Explorer.
The NICE CDF list Section B will be reviewed on a monthly basis. Any new SACT drugs brought into routine commissioning under Section B (NICE & NHS England approved cancer drugs/indications routinely funded by NHS England from 1 April 2016, including CDF and non-CDF approved drugs) will be added on to the dashboard. All treatments with a publication date prior to 1 January 2019 have been excluded from analysis.
Feedback and support
The NDRS SACT team welcomes your feedback on the new report and is happy to help with any queries you may have. If you would like to provide feedback, or if you would like support or further information about this work, then please do not hesitate to contact us via the SACT helpdesk at [email protected].